NOVAVAX INC (NVAX)
US6700024010 - Common Stock
NVAX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 612 industry peers in the Biotechnology industry. Both the profitability and financial health of NVAX have multiple concerns. While showing a medium growth rate, NVAX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year NVAX has reported negative net income.
In the past year NVAX has reported a negative cash flow from operations.
NVAX had negative earnings in each of the past 5 years.
NVAX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
NVAX has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVAX has a Gross Margin of 55.82%. This is in the better half of the industry: NVAX outperforms 79.14% of its industry peers.
The Profit Margin and Operating Margin are not available for NVAX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM | N/A | ||
| GM | 55.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
NVAX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NVAX has been increased compared to 5 years ago.
Compared to 1 year ago, NVAX has a worse debt to assets ratio.
2.2 Solvency
NVAX has an Altman-Z score of -4.17. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NVAX (-4.17) is worse than 63.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.17 |
ROIC/WACCN/A
WACC8.3%
2.3 Liquidity
NVAX has a Current Ratio of 0.71. This is a bad value and indicates that NVAX is not financially healthy enough and could expect problems in meeting its short term obligations.
NVAX has a Current ratio of 0.71. This is amonst the worse of the industry: NVAX underperforms 94.21% of its industry peers.
A Quick Ratio of 0.69 indicates that NVAX may have some problems paying its short term obligations.
With a Quick ratio value of 0.69, NVAX is not doing good in the industry: 93.87% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.71 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 62.69% over the past year.
Looking at the last year, NVAX shows a very strong growth in Revenue. The Revenue has grown by 23.74%.
NVAX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.40% yearly.
EPS 1Y62.69%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q108.88%
Revenue growth 1Y23.74%
Revenue growth 3Y373.24%
Revenue growth 5Y129.4%
Revenue growth Q2Q128.28%
3.2 Future
Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.34% on average per year.
The Revenue is expected to decrease by -5.29% on average over the next years.
EPS Next Y81.64%
EPS Next 2Y37.7%
EPS Next 3Y23.93%
EPS Next 5Y17.34%
Revenue Next Year-32.08%
Revenue Next 2Y-19.78%
Revenue Next 3Y-17.86%
Revenue Next 5Y-5.29%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NVAX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVAX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NVAX's earnings are expected to grow with 23.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.7%
EPS Next 3Y23.93%
5. Dividend
5.1 Amount
NVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NOVAVAX INC
NASDAQ:NVAX (9/27/2023, 1:27:01 PM)
7.1
-0.01 (-0.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)11-06 2023-11-06/amc
Inst Owners60.96%
Inst Owner Change-4.25%
Ins Owners0.32%
Ins Owner Change10.44%
Market Cap670.27M
Analysts75
Price Target21.01 (195.92%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)72.22%
Min EPS beat(2)3.43%
Max EPS beat(2)141.01%
EPS beat(4)2
Avg EPS beat(4)-58.23%
Min EPS beat(4)-234.4%
Max EPS beat(4)141.01%
Revenue beat(2)2
Avg Revenue beat(2)132187%
Min Revenue beat(2)90485.5%
Max Revenue beat(2)173888%
Revenue beat(4)4
Avg Revenue beat(4)119617%
Min Revenue beat(4)90485.5%
Max Revenue beat(4)173888%
PT rev (1m)-6.36%
PT rev (3m)-6.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-240.52%
EPS NY rev (1m)8.36%
EPS NY rev (3m)72.62%
Revenue NQ rev (1m)-99.9%
Revenue NQ rev (3m)-99.93%
Revenue NY rev (1m)-5.12%
Revenue NY rev (3m)63.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-7.26
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-7.76
FCFYN/A
OCF(TTM)-6.93
OCFYN/A
SpS16.92
BVpS-7.99
TBVpS-9.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | 55.82% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 225.95% | ||
| Cap/Sales | 4.91% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.71 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | -4.17 |
F-Score2
WACC8.3%
ROIC/WACCN/A
Cap/Depr(3y)630.35%
Cap/Depr(5y)388.12%
Cap/Sales(3y)7.06%
Cap/Sales(5y)7.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y62.69%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q108.88%
EPS Next Y81.64%
EPS Next 2Y37.7%
EPS Next 3Y23.93%
EPS Next 5Y17.34%
Revenue growth 1Y23.74%
Revenue growth 3Y373.24%
Revenue growth 5Y129.4%
Revenue growth Q2Q128.28%
Revenue Next Year-32.08%
Revenue Next 2Y-19.78%
Revenue Next 3Y-17.86%
Revenue Next 5Y-5.29%
EBIT growth 1Y56.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.12%
EBIT Next 3Y19.62%
EBIT Next 5YN/A
FCF growth 1Y-223.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-197.26%
OCF growth 3YN/A
OCF growth 5YN/A